Up a level |
Townsend, Tristan, Razanskaite, Violeta, Dodd, Susanna ORCID: 0000-0003-2851-3337, Storey, Daniel, Michail, Stephanie, Morgan, James, Davies, Michael, Penman, Douglas, Watters, Christopher, Swaminathan, Mira et al (show 7 more authors)
(2020)
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease.
Alimentary Pharmacology and Therapeutics, 52 (8).
pp. 1341-1352.
Burkitt, Michael D ORCID: 0000-0002-5055-6408, Williams, Jonathan M, Townsend, Tristan, Hough, Rachael and Pritchard, D Mark ORCID: 0000-0001-7971-3561
(2017)
Mice lacking NF-κB1 exhibit marked DNA damage responses and more severe gastric pathology in response to intraperitoneal tamoxifen administration.
CELL DEATH & DISEASE, 8 (7).
e2939-.
Burkitt, Michael ORCID: 0000-0002-5055-6408, Williams, Jonathan, Townsend, Tristan, Hough, Rachael, Duckworth, Carrie and Pritchard, David Mark ORCID: 0000-0001-7971-3561
(2017)
Mice lacking NF-κB1 exhibit marked DNA damage responses and more severe gastric pathology in response to intraperitoneal tamoxifen administration.
Cell Death and Disease.
112656-.
Townsend, Tristan, Campbell, Fiona, O'Toole, Paul and Probert, Chris ORCID: 0000-0003-4550-0239
(2019)
Microscopic colitis: diagnosis and management.
FRONTLINE GASTROENTEROLOGY, 10 (4).
pp. 388-393.
Lenti, Marco Vincenzo, Dolby, Vivien, Clark, Tanya, Hall, Veronica, Tattersall, Suzanne, Fairhurst, Francesca, Kenneth, Catherine, Walker, Rachael, Kemp, Karen, Borg-Bartolo, Simon et al (show 11 more authors)
(2022)
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55 (7).
pp. 856-866.